PROFILE OF MEDICATION USE AND HEALTH OF PATIENTS WITH RHEUMATOID ARTHRITIS ATTENDED IN A RHEUMATOID ARTHRITIS AMBULATORY CLINIC OF A UNIVERSITY HOSPITAL

PROFILE OF MEDICATION USE AND HEALTH OF PATIENTS WITH RHEUMATOID ARTHRITIS ATTENDED IN A RHEUMATOID ARTHRITIS AMBULATORY CLINIC OF A UNIVERSITY HOSPITAL

GONÇALVES, THUANE SALES; OLIVEIRA, ISABELA VIANA; SILVA, HÁGABO MATHYELL; NEVES, CARINA MORAIS; NASCIMENTO, MARIANA MARTINS GONZAGA; OLIVEIRA, DJENANE RAMALHO DE

Pôster:

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease of an autoimmune nature that affects the synovial membrane of the joints and, when not properly treated, causes loss of functional capacity and increased mortality. The treatment of RA involves different types of drugs with pre-established criteria of use that are adopted as the patient evolves. The safety profile of these drugs and the heterogeneity of their action require regular monitoring of their effectiveness and safety parameters. The aim of the present study was to describe the profile of drug use and health of patients with RA attended in a rheumatology clinic.

Materials and methods

This is a cross-sectional study based on the medical records of 201 patients.

Results

An average age of 60 years were detected. In addition to RA, 97.5% of the patients had at least one other comorbidity, and systemic arterial hypertension (52.7%) was the most prevalent. The patients used a total of 1,826 medications, with an average of 9.1 ± 3.3 and 94.5% used 5 or more medications. The most commonly used agent for the treatment of RA was prednisone (53.2%), followed by methotrexate (50.7%), leflunomide (42.3%), and biological agents (41.8%). The majority of the patients (89.6%) also used at least one adjuvant medication to control adverse effects and 31.3% also used at least one adjuvant medication to contro

Conclusion

It was evidenced a complex profile of drug use due to the characteristics of the disease and associated comorbidities, which requires an adequate global approach to patients’ drug therapy.

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease of an autoimmune nature that affects the synovial membrane of the joints and, when not properly treated, causes loss of functional capacity and increased mortality. The treatment of RA involves different types of drugs with pre-established criteria of use that are adopted as the patient evolves. The safety profile of these drugs and the heterogeneity of their action require regular monitoring of their effectiveness and safety parameters. The aim of the present study was to describe the profile of drug use and health of patients with RA attended in a rheumatology clinic.

Materials and methods

This is a cross-sectional study based on the medical records of 201 patients.

Results

An average age of 60 years were detected. In addition to RA, 97.5% of the patients had at least one other comorbidity, and systemic arterial hypertension (52.7%) was the most prevalent. The patients used a total of 1,826 medications, with an average of 9.1 ± 3.3 and 94.5% used 5 or more medications. The most commonly used agent for the treatment of RA was prednisone (53.2%), followed by methotrexate (50.7%), leflunomide (42.3%), and biological agents (41.8%). The majority of the patients (89.6%) also used at least one adjuvant medication to control adverse effects and 31.3% also used at least one adjuvant medication to contro

Conclusion

It was evidenced a complex profile of drug use due to the characteristics of the disease and associated comorbidities, which requires an adequate global approach to patients’ drug therapy.

Palavras-chave:

DOI: 10.5151/sbr2019-555

Referências bibliográficas

• [1]

Como citar:

GONÇALVES, THUANE SALES; OLIVEIRA, ISABELA VIANA; SILVA, HÁGABO MATHYELL; NEVES, CARINA MORAIS; NASCIMENTO, MARIANA MARTINS GONZAGA; OLIVEIRA, DJENANE RAMALHO DE; "PROFILE OF MEDICATION USE AND HEALTH OF PATIENTS WITH RHEUMATOID ARTHRITIS ATTENDED IN A RHEUMATOID ARTHRITIS AMBULATORY CLINIC OF A UNIVERSITY HOSPITAL", p-555-555. In: Anais do 36º Congresso Brasileiro de Reumatologia. [ISBN 978-85-212-1892-0]. São Paulo: Blucher, 2019.
ISSN 23577282, DOI 10.5151/sbr2019-555